Know Cancer

or
forgot password

Continuing Access To The Tyrosine Kinase Inhibitor Of VEGFR 2, AG-013736 (A406) For Patients Previously Receiving AG-013736 In Clinical Trials


N/A
N/A
N/A
Open (Enrolling)
Both
Solid Tumors

Thank you

Trial Information

Continuing Access To The Tyrosine Kinase Inhibitor Of VEGFR 2, AG-013736 (A406) For Patients Previously Receiving AG-013736 In Clinical Trials


Inclusion Criteria:



- Patients who were assigned to an axitinib containing treatment arm in a previous
clinical trial

- Patients who were receiving axitinib tablets at the time their previous trial ended

- Patients who have stable (SD) or responding disease (PR or CR) documented by the
appropriate radiological, clinical, or laboratory assessments within 12 weeks before
enrollment (Note: response criteria from the previous AG-013736 protocol should be
used to determine stable or responding disease).

- Patients who have progressive disease (PD) but have experienced "clinical benefit"
as defined in the study protocol

Exclusion Criteria:

- Patients may not participate in this trial if the conditions for continuing treatment
in the previous AG-013736 protocol are not met

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety, especially thyroid gland abnormalities will be assessed using regular measurements of thyroid stimulating hormone in blood.

Outcome Time Frame:

10 Oct 2010

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A4061008

NCT ID:

NCT00828919

Start Date:

March 2003

Completion Date:

December 2015

Related Keywords:

  • Solid Tumors
  • VEGFR inhibitor
  • angi-angiogenic
  • tyrosine kinase inhibitor

Name

Location

Pfizer Investigational SiteBlendora, California  91740
Pfizer Investigational SiteDetroit, Michigan  48201
Pfizer Investigational SiteCincinnait, Ohio  45236
Pfizer Investigational SiteSpringfield, Illinois  62701-1014
Pfizer Investigational SiteBronx, New York  10461
Pfizer Investigational SiteHouston, Texas  77030
Pfizer Investigational SiteFederal Way, Washington  98003
Pfizer Investigational SiteWestminster, Maryland  21157
Pfizer Investigational SiteKingston, Pennsylvania  18704-5535
Pfizer Investigational SiteMilwaukee, Wisconsin  53215